Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Investment Securities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 10 years of Gains from Investment Securities data on record, last reported at $11.7 million in Q4 2024.

  • For Q4 2024, Gains from Investment Securities rose 9.39% year-over-year to $11.7 million; the TTM value through Dec 2024 reached $11.7 million, up 9.39%, while the annual FY2025 figure was $3.1 million, 73.82% down from the prior year.
  • Gains from Investment Securities reached $11.7 million in Q4 2024 per SNDX's latest filing, up from $10.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.7 million in Q4 2024 and bottomed at -$3000.0 in Q3 2020.
  • Average Gains from Investment Securities over 5 years is $3.0 million, with a median of $712173.5 recorded in 2020.
  • Peak YoY movement for Gains from Investment Securities: tumbled 150.0% in 2020, then soared 3866.96% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $1000.0 in 2020, then skyrocketed by 229900.0% to $2.3 million in 2021, then soared by 247.03% to $8.0 million in 2022, then surged by 33.87% to $10.7 million in 2023, then rose by 9.39% to $11.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $11.7 million in Q4 2024, $10.7 million in Q4 2023, and $308550.0 in Q3 2023.